TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00101348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01918137

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: chocolate bar

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Porridge
Study: NCT01023412

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Immunonutrition
Description: Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Immunonutrition
Description: Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
Study: NCT01202227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Pregabalin capsules taken twice a daily (150-600mg/day)
Study: NCT03456713

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY3074828
Description: Administered SC
Study: NCT03926767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE)
Description: A power-point presentation with metaphors and animated videos will be employed. The PNE program will be held in 2 sessions of 30 minutes each. The intervention program will be divided into 17 thematic topics according to Explain Pain.
Study: NCT03490994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 20mg qd (15mg qd when CrCl 30-49 ml/min using creatinine-based CKD-EPI equations) for 6 months
Study: NCT00940160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAX576
Study: NCT03490994

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin + LMWH
Description: dose-adjusted warfarin (target INR 2-3) for 6 months + LMWH (enoxaparin 1 mg/kg q12h for a few days until INR target achieved) if indicated
Study: NCT01343212

Intervention type: OTHER
Intervention: stiffness measurement using ARFI
Description: Stiffness measurement will be performed for HCC using ARFI technique.
Study: NCT03926767

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial Manual Therapy
Description: A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orofacial Manual Therapy
Description: A protocol of Orofacial Exercises and Manual Therapy will be adopted in the present study. The manual therapy techniques will be: Intraoral temporalis release, Intraoral medial and lateral pterygoid (origin) technique and Intraoral sphenopalatine ganglion technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial Exercises
Description: Two mandibular exercises: Mandibular body-condylar cross-pressure chewing technique and Post-isometric relaxation stretches-laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.
Study: NCT00770393

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: induction chemotherapy
Description: Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventionnal chemotherapy
Description: Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.~- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion.
Study: NCT00133445

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-Hep B-IPV Vaccine
Description: U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTaP-Hep B-IPV Vaccine
Description: U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent Hep B Vaccine
Description: U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
Study: NCT02184533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium selenite
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT03175107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exergaming
Study: NCT01197547

Intervention type: DEVICE
Group type: OTHER
Intervention: Genesys HTA
Description: Genesys HTA Endometrial Ablation
Study: NCT04858373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study: NCT00940160

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAX576

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: QAX576
Study: NCT03926767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orofacial Exercises
Description: Two mandibular exercises: Mandibular body-condylar cross-pressure chewing technique and Post-isometric relaxation stretches-laterotrusion and opening. Each exercise will be executed 10 times per session for 10 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neck Motor Control Exercises
Description: A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
Study: NCT02139046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat IR
Description: Febuxostat IR over-encapsulated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat IR
Description: Febuxostat IR over-encapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat XR over-encapsulated capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat XR
Description: Febuxostat XR over-encapsulated capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Febuxostat placebo
Description: Febuxostat placebo-matching capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine tablets
Study: NCT03926767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck Motor Control Exercises
Description: A protocol of neck motor control protocol will be adopted in our study. The exercises included bracing exercises (six hierarchical levels) in neurodevelopment stages for the cervical spine. Extremity range of motion exercises will be conducted while maintaining a stable spine at the specific positions. Also, cervical isometric exercises (five hierarchical levels) will be carried out directly forward, obliquely, toward right and left, and directly backward by maintaining a stable spine with elastic resistive bands. Finally, exercises also included functional training with elastic resistance and exercise balls on unstable surfaces (eight hierarchical levels). The criteria to progress in each exercise domain (bracing, isometric exercises or functional training) will be sustain the contraction for 10 seconds, 10 times.
Study: NCT04496596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suramin
Description: Suramin is administered via IV infusion as a single dose of 3 mg/kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04128579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itolizumab [Bmab 600]
Description: EQ001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itolizumab [Bmab 600]
Description: EQ001
Study: NCT02938585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: turoctocog alfa
Description: Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
Study: NCT01172587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Couples Therapy
Description: Couples participate in 12 sessions of Behavioral Couples Therapy designed to reduce substance use and increase relationship functioning.
Study: NCT00657852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disodium pamidronate
Description: Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
Study: NCT01919918

Intervention type: DRUG
Group type: OTHER
Intervention: Muscle Contraction with Metabolite Solution Administration
Description: Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6

Intervention type: DRUG
Group type: OTHER
Intervention: Muscle Contraction with Metabolite Solution Administration
Description: Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
Study: NCT01405313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified Adaptive Servoventilation Device
Description: The modified ASV has a greater adaptive response to meet a target ventilation level that is constantly being assessed.
Study: NCT02139046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naproxen
Description: Naproxen tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study: NCT00940160

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04691375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy: PY314 + Pembrolizumab
Description: Dose of PY314 alone and given in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy: PY314 + Pembrolizumab
Description: Dose of PY314 alone and given in combination with pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination Therapy: PY314 + Pembrolizumab
Description: Dose of PY314 alone and given in combination with pembrolizumab
Study: NCT02667678

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cohort HIVOL, patients infected by HIV
Description: Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance. The aim of this study is to check the renal function of the patients infected by HIV.
Study: NCT04621916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FVIII
Description: This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emicizumab
Description: This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emicizumab
Description: This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.
Study: NCT03714555

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Safety Laboratories
Description: Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Safety Laboratories
Description: Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Safety Laboratories
Description: Complete blood cell count (CBC) w Differential, comprehensive metabolic panel (CMP), Prothrombin time/international normalized ratio (PT/INR) Activated Partial Thromboplastin Time (aPTT), Urinalysis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AE Assessment
Description: Assessment of Adverse Events (AE)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AE Assessment
Description: Assessment of Adverse Events (AE)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AE Assessment
Description: Assessment of Adverse Events (AE)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exam
Description: Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exam
Description: Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exam
Description: Physical Exam, Weight, Vital Signs, Eastern Cooperative Oncology Group (ECOG) Performance Status
Study: NCT02139046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Lansoprazole capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lansoprazole
Description: Lansoprazole capsules
Study: NCT03714555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant Medication Review
Description: Prior and Concomitant Medication Review

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant Medication Review
Description: Prior and Concomitant Medication Review

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant Medication Review
Description: Prior and Concomitant Medication Review

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tumor Imaging
Description: Tumor CT or MRI

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tumor Imaging
Description: Tumor CT or MRI

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tumor Imaging
Description: Tumor CT or MRI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate
Description: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate
Description: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) Protocol Plus Disulfiram/Copper Gluconate
Description: nab-paclitaxel (Abraxane)/gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate
Description: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate
Description: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate
Description: FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate dispensing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
Description: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
Description: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate
Description: Single-agent gemcitabine (Gemzar) regimen Plus Disulfiram/Copper Gluconate dispensing
Study: NCT04858373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose as reference food
Description: Fourteen healthy, normal weight subjects (male: 6, female: 8) after 10-14 hr fast, consumed 50g glucose diluted in 300ml water, tested three times, in different visits, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
Study: NCT01405313

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Adaptive Servoventilation device
Description: Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed.
Study: NCT05617586

Intervention type: OTHER
Intervention: In-depth parental interview
Description: A semi-structurerd interview will be conducted of parents with a child diagnosed with DCD. The interview will be audio-recorderded. The audiofile will be transcribed ad-verbatim and analyzed using narrative analysis methods.

Intervention type: OTHER
Intervention: Developmental Coordination Disorder Questionnaire (DCD-Q)
Description: Parents will be asked to complete the DCD-Q. This will help us describe the sample.
Study: NCT00719108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wosulin R
Description: Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Actrapid
Description: Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.